Cessation Therapeutics is developing a monoclonal antibody therapy that binds fentanyl and its analogs in the bloodstream, preventing them from crossing the blood‑brain barrier and causing respiratory depression. The treatment provides long‑acting, systemic protection after a single or limited dosing regimen, offering a preventive option for healthcare providers, addiction programs, and public‑health agencies targeting high‑risk individuals.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Fentanyl and its analogs cause rapid, life‑threatening respiratory depression, leading to a high number of overdose deaths, especially among adults aged 18‑45. Current interventions rely on emergency treatment after overdose has occurred, offering limited preventive protection.
Solution
Cessation Therapeutics is developing a monoclonal antibody therapy that binds fentanyl molecules in the bloodstream, preventing them from crossing the blood‑brain barrier. By sequestering fentanyl before it reaches neuronal receptors, the treatment blocks both the euphoric effects and the respiratory depression that cause fatal overdoses. The antibody is designed for durable, systemic protection, providing ongoing immunity after a single or limited dosing regimen. This preventive approach aims to reduce the incidence of overdose events and lessen the burden on emergency medical services.
Target Audience
Primary customers are healthcare providers, addiction treatment programs, and public‑health agencies seeking preventive solutions for individuals at high risk of fentanyl exposure.
Features
- Highly specific anti‑fentanyl monoclonal antibody that captures fentanyl and related analogs in circulation
- Mechanism that blocks fentanyl entry into the brain, eliminating its pharmacologic effects
- Designed for long‑acting systemic protection, reducing the need for frequent dosing
- Potential for administration via standard injectable routes compatible with existing clinical workflows
- Safety profile focused on neutralizing only fentanyl molecules without affecting endogenous opioids